TRDA - NASDAQ
Entrada Therapeutics, Inc.
$6.64
-0.90%Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
At a Glance
Live Snapshottrda
Total Non-Current Assets
Last Annual Value
71.13M
3-Year CAGR
19%
5-Year CAGR
82%
10-Year CAGR
57%
Entrada Therapeutics, Inc. Competitors Analysis of Total Non-Current Assets
| Company | Total Non-Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Entrada Therapeutics, Inc. NASDAQ:TRDA | 71.13M | -10.6% | 58.4% | N/A | |
 Humacyte, Inc. NASDAQ:HUMA | 48.57M | 2.6% | -3.2% | N/A | |
 Immuneering Corporation NASDAQ:IMRX | 55.74M | 60.4% | 31.1% | N/A | |
 Allogene Therapeutics, Inc. NASDAQ:ALLO | 158.16M | -4.9% | -22.9% | N/A | |
 Caribou Biosciences, Inc. NASDAQ:CRBU | 30.14M | -31.4% | -10.0% | N/A | |
 Enanta Pharmaceuticals, Inc. NASDAQ:ENTA | 76.40M | 24.6% | -8.9% | 4.5% | |
 Foghorn Therapeutics Inc. NASDAQ:FHTX | 34.87M | -8.6% | -10.4% | N/A | |
 OmniAb, Inc. NASDAQ:OABI | 235.57M | -5.6% | -3.5% | N/A | |
 Pyxis Oncology, Inc. NASDAQ:PYXS | 19.41M | -26.6% | 70.5% | N/A | |
 Cassava Sciences, Inc. NASDAQ:SAVA | 20.65M | -2.1% | -1.5% | 56.7% | |
 Sangamo Therapeutics, Inc. NASDAQ:SGMO | 23.91M | -30.4% | -40.6% | 11.1% |
Entrada Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your TRDA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.